同步放化疗与序贯放化疗治疗Ⅲ期非小细胞肺癌的临床疗效比较  

Comparison of the Clinical Efficacy of Concurrent Chemoradiotherapy Versus Sequential Chemotherapy for Stage Ⅲ Non-small Cell Lung Cancer

作　　者：刘晓梅[1] 王晓华[1] 周强[1] 

机构地区：[1]四川省遂宁市中心医院,629000

出　　处：《实用癌症杂志》2016年第9期1476-1479,共4页The Practical Journal of Cancer

摘　　要：目的探讨Ⅲ期非小细胞肺癌同步放化疗与序贯放化疗的临床疗效。方法回顾性分析84例Ⅲ期非小细胞肺癌患者的临床资料,根据放疗方法不同分为同步放疗组和序贯放化疗组,对治疗前和治疗后1周2组患者的相关实验指标[血管内皮生长因子(VEGF)、癌胚抗原(CEA)、细胞角蛋白19的可溶性片段(CYFRA21-1)、缺氧诱导因子(HiF-1a)、Monototal、DKK-1]、治疗有效率、不良反应发生率和相关功能进行比较。结果治疗后1周,同步放疗组相关实验指标(VEGF、DKK-1)、治疗的总有效率、生理评分和生活质量评分均优于序贯放化疗组(P<0.05),白细胞下降的发生率低于序贯放化疗组(P=0.008),其他不良反应在2组之间无统计学差异(P>0.05)。结论与序贯放化疗相比,同步放化疗治疗Ⅲ期非小细胞肺癌可提高临床疗效,提高患者的VEGF和DKK-1水平,改善患者的生理功能及生活质量。Objective To investigate the clinical efficacy of concurrent chemoradiotherapy versus sequential chemothera- py for stage HI non-small cell lung cancer. Methods The clinical data of 84 patients with stage HI non-small cell lung cancer were retrospectively analyzed. 84 patients were divided into concurrent radiotherapy group and sequential chemoradiotherapy group according to different radiotherapy methods. Related experimental indicators[ vessels endothelial growth factor（ VEGF）, carcino- embryonic antigen （ CEA）, cytokeratin soluble fragments （ CYFRA21-1 ） 19, and hypoxia-inducible factor （ HiF-1 a）, Monototal, DKK-1 ] ,treatment efficiency,adverse reactions rates and related functions before treatment and 1 week after treatment of the 2 groups were compared. Results 1 week after treatment, the related laboratory parameters （VEGF, DKK-1 ）, the total efficiency of the treatment, physiology score and quality of life scores in concurrent radiotherapy group were better than those of sequential che- moradiation group（P 〈 0.05）. The incidence rate of leukopenia in concurrent radiotherapy group was lower than than that of se- quential chemoradiotherapy group （P = 0. 008 ）, and adverse reactions between the 2 group had no significant difference （ P 〉 0.05）. Conclusion Compared with sequential chemotherapy, concurrent chemoradiotherapy for stage 111 non-small cell lung cancer can improve clinical efficacy,levels of VEGF and DKK-1 ,physical function and quality of life.

关 键 词：同步放化疗 序贯放化疗 三维适形 Ⅲ期非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]